Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion

被引：31

作者：

Huang, Shang -Chin ^{[1
,2
,3
,4
]}

Su, Tung -Hung ^{[2
,3
]}

Tseng, Tai -Chung ^{[3
,5
]}

Chen, Chi -Ling ^{[4
]}

Hsu, Shih-Jer ^{[2
,3
]}

Liu, Chen-Hua ^{[2
,3
]}

Liao, Sih-Han ^{[6
]}

Hong, Chun -Ming ^{[7
]}

Lan, Ting -Yuan ^{[8
]}

Yang, Hung-Chih ^{[2
,3
]}

Liu, Chun-Jen ^{[2
,3
,4
]}

Chen, Pei-Jer ^{[2
,3
,4
,5
]}

Kao, Jia-Horng ^{[2
,3
,4
,9
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Internal Med, Bei Hu Branch, Taipei, Taiwan

[2] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, 1 Chang Te St, Taipei 10048, Taiwan

[3] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan

[4] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan

[6] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[7] Natl Taiwan Univ Hosp, Div Hosp Med, Dept Internal Med, Taipei, Taiwan

[8] Natl Taiwan Univ Hosp, Dept Internal Med, Div Rheumatol, Hsin Chu Branch, Hsinchu, Taiwan

[9] Natl Taiwan Univ, Coll Med, 1 Chang Te St, Taipei 10048, Taiwan

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 22卷 / 03期

关键词：

No steatosis; = Steatosis only; HBSAG SEROCLEARANCE; NEGATIVE PATIENTS; VIRUS INFECTION; DETERMINANTS; OUTCOMES; IMPACT;

D O I：

10.1016/j.cgh.2023.09.040

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND & AIMS: Hepatitis B surface antigen (HBsAg) seroclearance is the goal of functional cure for hepatitis B virus (HBV) infection. However, the impact of metabolic dysfunction -associated steatotic liver disease (MASLD) on this favorable outcome remains unclear. BACKGROUND & AIMS: METHODS: Hepatitis B surface antigen (HBsAg) seroclearance is the goal of functional cure for hepatitis B virus (HBV) infection. However, the impact of metabolic dysfunction -associated steatotic liver disease (MASLD) on this favorable outcome remains unclear. Patients with chronic hepatitis B (CHB) were consecutively recruited. MASLD was defined by the newly proposed disease criteria. Cumulative incidences and associated factors of HBsAg seroclearance/seroconversion were compared between the MASLD and non-MASLD groups. From 2006 to 2021, 4084 treatment -naive hepatitis B e antigen (HBeAg)-negative CHB patients were included. At baseline, CHB patients with concurrent MASLD (n [ 887) had significantly

引用

页码：581 / 590

页数：10

共 35 条

[1] The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments [J].

Austin, Peter C. .

STATISTICS IN MEDICINE, 2014, 33 (07) :1242-1258

[2] CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease [J].

Breuer, Denitra A. ;

Pacheco, Maria Cristina ;

Washington, M. Kay ;

Montgomery, Stephanie A. ;

Hasty, Alyssa H. ;

Kennedy, Arion J. .

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2020, 318 (02) :G211-G224

[3] Ten reasons gastroenterologists and hepatologists should be treating obesity [J].

Camilleri, Michael ;

El-Omar, Emad M. .

GUT, 2023, 72 (06) :1033-+

[4] Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection [J].

Cao, Jing ;

Gong, Jiao ;

Tsia Hin Fong, Christ-Jonathan ;

Xiao, Cuicui ;

Lin, Guoli ;

Li, Xiangyong ;

Jie, Yusheng ;

Chong, Yutian .

BIOMED RESEARCH INTERNATIONAL, 2020, 2020

[5] Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? [J].

Chu, C-M ;

Lin, D-Y ;

Liaw, Y-F .

INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 (05) :871-875

[6] Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without [J].

Chu, Chia-Ming ;

Lin, Deng-Yn ;

Liaw, Yun-Fan .

DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (01) :275-281

[7] New Approaches to Chronic Hepatitis B [J].

Dusheiko, Geoffrey ;

Agarwal, Kosh ;

Maini, Mala K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01) :55-69

[8] Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B [J].

Hsueh, Rei-Chi ;

Wu, Wan-Jung ;

Lin, Chih-Lin ;

Liu, Chun-Jen ;

Huang, Yi-Wen ;

Hu, Jui-Ting ;

Wu, Chih-Feng ;

Sung, Feng-Yu ;

Liu, Wen-Jie ;

Yu, Ming-Whei .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 :301-313

[9] The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study [J].

Huang, Jiaofeng ;

Jing, Mengli ;

Wang, Ciyang ;

Wang, Mingfang ;

You, Shunjie ;

Lin, Su ;

Zhu, Yueyong .

JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (08) :1191-1197

[10] Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B [J].

Huang, Shang-Chin ;

Su, Tung-Hung ;

Tseng, Tai-Chung ;

Chen, Chi-Ling ;

Hsu, Shih-Jer ;

Liao, Sih-Han ;

Hong, Chun-Ming ;

Liu, Chen-Hua ;

Lan, Ting-Yuan ;

Yang, Hung-Chih ;

Liu, Chun-Jen ;

Chen, Pei-Jer ;

Kao, Jia-Horng .

HEPATOLOGY INTERNATIONAL, 2023, 17 (05) :1139-1149

← 1 2 3 4 →